B. Riley analyst Mayank Mamtani lowered the firm’s price target on Agenus to $5 from $6 and keeps a Buy rating on the shares. The company’s Q4 earnings focused on the roadmap to BOT/BAL U.S. and EU accelerated approval submission, with management reiterating their bullish view on BOT/BAL in terms of efficacy, safety, and commercial opportunity, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AGEN:
- Agenus Inc.’s Future at Risk: Concerns Over Financial Health and Operational Viability
- Agenus reports Q4 EPS (13c) vs. (24c) last year
- AGEN Earnings this Week: How Will it Perform?
- Options Volatility and Implied Earnings Moves This Week, March 11 – March 15, 2024
- Agenus Announces 1:20 Reverse Stock Split Effective February 2024
